Learn more about our research, therapeutic areas of focus, technologies, and publications
Translating research into innovative therapeutics
Adapted from Hanahan D, Cancer Discov (2022) 12 (1): 31–46.
We develop innovative therapeutics that address several hallmarks of cancer utilizing our expertise in medicinal chemistry, toxicology, pharmacology, translational research, and clinical research.
Our new drug target ideation team is constantly evaluating and assessing various opportunities to initiate new programs. We select novel oncology targets that are amenable to therapeutic interventions – evaluating them for disease relevance, efficacy, and safety.
We discover and develop innovative treatments in multiple focus areas in oncology
We have established multiple platforms to support advanced research and generation of clinical candidates
Protein degraders are powerful tools to chemically silence targets of interest including those that are previously considered undruggable. Being an early adopter, our unique platform accelerates the identification of these degraders with zero or minimal linker between ligands of E3 ligase and target proteins.
One of the examples, AU-15330 is a SMARCA2/4 selective tool degrader created using the platform. With one of the smallest molecular weights in the class, AU-15330 has proven effective in multiple oncology models including CRPC, both as a single agent and in combination with SOC.